Neurocrine Biosciences (NBIX) Reports Q3 Loss of $0.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $168.02 +15.60%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of ($0.13), versus ($0.43) reported last year.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Regal Rexnord Corporation (RRX) Tops Q3 EPS by 25c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
